Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

MDMA Impairs Response to Water Intake in Healthy Volunteers.

Baggott MJ, Garrison KJ, Coyle JR, Galloway GP, Barnes AJ, Huestis MA, Mendelson JE.

Adv Pharmacol Sci. 2016;2016:2175896. doi: 10.1155/2016/2175896. Epub 2016 Jun 14.

2.

Development and Testing of a Smartphone-Based Cognitive/Neuropsychological Evaluation System for Substance Abusers.

Pal R, Mendelson J, Clavier O, Baggott MJ, Coyle J, Galloway GP.

J Psychoactive Drugs. 2016 Sep-Oct;48(4):288-94. doi: 10.1080/02791072.2016.1191093. Epub 2016 Jun 3.

PMID:
27260123
3.

Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting.

Baggott MJ, Coyle JR, Siegrist JD, Garrison KJ, Galloway GP, Mendelson JE.

J Psychopharmacol. 2016 Apr;30(4):378-87. doi: 10.1177/0269881115626348. Epub 2016 Feb 15.

PMID:
26880224
4.

Intensive Motivational Interviewing for Women with Alcohol Problems.

Korcha RA, Polcin DL, Evans K, Bond JC, Galloway GP.

Counselor (Deerfield Beach). 2015 Jun;16(3):62-69.

5.

Text messaging for addiction: a review.

Keoleian V, Polcin D, Galloway GP.

J Psychoactive Drugs. 2015 Apr-Jun;47(2):158-76. doi: 10.1080/02791072.2015.1009200. Review.

6.

Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.

Anderson AL, Li SH, Markova D, Holmes TH, Chiang N, Kahn R, Campbell J, Dickerson DL, Galloway GP, Haning W, Roache JD, Stock C, Elkashef AM.

Drug Alcohol Depend. 2015 May 1;150:170-4. doi: 10.1016/j.drugalcdep.2015.01.036. Epub 2015 Feb 7.

7.

Impact of prospectively determined A118G polymorphism on treatment response to injectable naltrexone among methamphetamine-dependent patients: an open-label, pilot study.

Pal R, Mendelson JE, Flower K, Garrison K, Yount G, Coyle JR, Galloway GP.

J Addict Med. 2015 Mar-Apr;9(2):130-5. doi: 10.1097/ADM.0000000000000107.

8.

Randomized trial of intensive motivational interviewing for methamphetamine dependence.

Polcin DL, Bond J, Korcha R, Nayak MB, Galloway GP, Evans K.

J Addict Dis. 2014;33(3):253-65. doi: 10.1080/10550887.2014.950029.

9.

MDMA effects consistent across laboratories.

Kirkpatrick MG, Baggott MJ, Mendelson JE, Galloway GP, Liechti ME, Hysek CM, de Wit H.

Psychopharmacology (Berl). 2014 Oct;231(19):3899-905. doi: 10.1007/s00213-014-3528-z. Epub 2014 Mar 15.

10.

Assessment of safety, cardiovascular and subjective effects after intravenous cocaine and lofexidine.

De La Garza R 2nd, Galloway GP, Newton TF, Mendelson J, Haile CN, Dib E, Hawkins RY, Chen CY, Mahoney JJ 3rd, Mojsiak J, Lao G, Anderson A, Kahn R.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Apr 3;50:44-52. doi: 10.1016/j.pnpbp.2013.11.013. Epub 2013 Dec 4.

11.

Intensive motivational interviewing for women with concurrent alcohol problems and methamphetamine dependence.

Korcha RA, Polcin DL, Evans K, Bond JC, Galloway GP.

J Subst Abuse Treat. 2014 Feb;46(2):113-9. doi: 10.1016/j.jsat.2013.08.013. Epub 2013 Sep 26.

12.

A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence.

Somoza EC, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA, Galloway GP, Segal SD, Sheehan M, Roache JD, Bickel WK, Jasinski D, Watson DW, Miller SR, Somoza P, Winhusen T.

JAMA Psychiatry. 2013 Jun;70(6):630-7. doi: 10.1001/jamapsychiatry.2013.872.

PMID:
23575810
13.

Ketamine is associated with lower urinary tract signs and symptoms.

Pal R, Balt S, Erowid E, Erowid F, Baggott MJ, Mendelson J, Galloway GP.

Drug Alcohol Depend. 2013 Sep 1;132(1-2):189-94. doi: 10.1016/j.drugalcdep.2013.02.005. Epub 2013 Mar 7.

PMID:
23474358
14.

A simple, novel method for assessing medication adherence: capsule photographs taken with cellular telephones.

Galloway GP, Coyle JR, Guillén JE, Flower K, Mendelson JE.

J Addict Med. 2011 Sep;5(3):170-4. doi: 10.1097/ADM.0b013e3181fcb5fd.

PMID:
21844832
15.

Mechanisms and genetics of antipsychotic-associated weight gain.

Balt SL, Galloway GP, Baggott MJ, Schwartz Z, Mendelson J.

Clin Pharmacol Ther. 2011 Jul;90(1):179-83. doi: 10.1038/clpt.2011.97. Epub 2011 Jun 1. Review. No abstract available.

PMID:
21633343
16.

A method to quantify illicit intake of drugs from urine: methamphetamine.

Li L, Galloway GP, Verotta D, Everhart ET, Baggott MJ, Coyle JR, Lopez JC, Mendelson J.

J Pharmacol Exp Ther. 2011 Jul;338(1):31-6. doi: 10.1124/jpet.111.179176. Epub 2011 Mar 30.

17.

A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction.

Galloway GP, Buscemi R, Coyle JR, Flower K, Siegrist JD, Fiske LA, Baggott MJ, Li L, Polcin D, Chen CY, Mendelson J.

Clin Pharmacol Ther. 2011 Feb;89(2):276-82. doi: 10.1038/clpt.2010.307. Epub 2010 Dec 22.

18.

Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.

Baggott MJ, Siegrist JD, Galloway GP, Robertson LC, Coyle JR, Mendelson JE.

PLoS One. 2010 Dec 2;5(12):e14074. doi: 10.1371/journal.pone.0014074.

19.

Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial.

Mendelson JE, Coyle JR, Lopez JC, Baggott MJ, Flower K, Everhart ET, Munro TA, Galloway GP, Cohen BM.

Psychopharmacology (Berl). 2011 Apr;214(4):933-9. doi: 10.1007/s00213-010-2103-5. Epub 2010 Dec 8.

20.

Psychiatric comorbidity in methamphetamine dependence.

Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP.

Psychiatry Res. 2011 Apr 30;186(2-3):356-61. doi: 10.1016/j.psychres.2010.09.014. Epub 2010 Nov 4.

21.

An examination of drug craving over time in abstinent methamphetamine users.

Galloway GP, Singleton EG, Buscemi R, Baggott MJ, Dickerhoof RM, Mendelson JE; Methamphetamine Treatment Project Corporate Authors.

Am J Addict. 2010 Nov-Dec;19(6):510-4. doi: 10.1111/j.1521-0391.2010.00082.x. Epub 2010 Sep 21.

PMID:
20958846
22.

Efficacy, safety, and ethics of cosmetic neurology far from settled.

Flower K, Li L, Chen CY, Baggott MJ, Galloway GP, Mendelson J.

Clin Pharmacol Ther. 2010 Oct;88(4):461-3. doi: 10.1038/clpt.2010.194.

PMID:
20856245
23.

Extended findings of brain metabolite normalization in MA-dependent subjects across sustained abstinence: a proton MRS study.

Salo R, Buonocore MH, Leamon M, Natsuaki Y, Waters C, Moore CD, Galloway GP, Nordahl TE.

Drug Alcohol Depend. 2011 Jan 15;113(2-3):133-8. doi: 10.1016/j.drugalcdep.2010.07.015. Epub 2010 Aug 23.

24.

Confirmatory Factor Analysis and Test-Retest Reliability of the Alcohol and Drug Confrontation Scale (ADCS).

Polcin DL, Galloway GP, Bond J, Korcha R, Greenfield TK.

J Drug Issues. 2009 Sep;39(4):931-948.

25.

Use patterns and self-reported effects of Salvia divinorum: an internet-based survey.

Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J.

Drug Alcohol Depend. 2010 Oct 1;111(3):250-6. doi: 10.1016/j.drugalcdep.2010.05.003.

PMID:
20627425
26.

Estimating the intake of abused methamphetamines using experimenter-administered deuterium labeled R-methamphetamine: selection of the R-methamphetamine dose.

Li L, Lopez JC, Galloway GP, Baggott MJ, Everhart T, Mendelson J.

Ther Drug Monit. 2010 Aug;32(4):504-7. doi: 10.1097/FTD.0b013e3181db82f2.

27.

How do residents of recovery houses experience confrontation between entry and 12-month follow-up?

Polcin DL, Galloway GP, Bond J, Korcha R, Greenfield TK.

J Psychoactive Drugs. 2010 Mar;42(1):49-62.

28.

Development of an acceptance-based coping intervention for alcohol dependence relapse prevention.

Vieten C, Astin JA, Buscemi R, Galloway GP.

Subst Abus. 2010 Apr;31(2):108-16. doi: 10.1080/08897071003641594.

PMID:
20408062
29.

Methamphetamine and paranoia: the methamphetamine experience questionnaire.

Leamon MH, Flower K, Salo RE, Nordahl TE, Kranzler HR, Galloway GP.

Am J Addict. 2010 Mar-Apr;19(2):155-68. doi: 10.1111/j.1521-0391.2009.00014.x.

30.

Imagery scripts and a computerized subtraction stress task both induce stress in methamphetamine users: a controlled laboratory study.

Garrison KJ, Coyle JR, Baggott MJ, Mendelson J, Galloway GP.

Subst Abuse. 2010;4:53-60. doi: 10.4137/SART.S6019. Epub 2010 Oct 26.

31.

How long does craving predict use of methamphetamine? Assessment of use one to seven weeks after the assessment of craving: Craving and ongoing methamphetamine use.

Galloway GP, Singleton EG; The Methamphetamine Treatment Project Corporate Authors.

Subst Abuse. 2009 Aug 26;1:63-79.

32.

Drug abstinence and cognitive control in methamphetamine-dependent individuals.

Salo R, Nordahl TE, Galloway GP, Moore CD, Waters C, Leamon MH.

J Subst Abuse Treat. 2009 Oct;37(3):292-7. doi: 10.1016/j.jsat.2009.03.004. Epub 2009 Mar 31.

33.

Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine.

Mendelson J, Flower K, Pletcher MJ, Galloway GP.

Exp Clin Psychopharmacol. 2008 Oct;16(5):435-41. doi: 10.1037/a0013637. Review.

34.

Cognitive control and white matter callosal microstructure in methamphetamine-dependent subjects: a diffusion tensor imaging study.

Salo R, Nordahl TE, Buonocore MH, Natsuaki Y, Waters C, Moore CD, Galloway GP, Leamon MH.

Biol Psychiatry. 2009 Jan 15;65(2):122-8. doi: 10.1016/j.biopsych.2008.08.004. Epub 2008 Sep 23.

35.

A nine session manual of motivational enhancement therapy for methamphetamine dependence: adherence and efficacy.

Galloway GP, Polcin D, Kielstein A, Brown M, Mendelson J.

J Psychoactive Drugs. 2007 Nov;Suppl 4:393-400.

PMID:
18286727
36.
37.

Methamphetamine users entering treatment: characteristics of the methamphetamine treatment project sample.

Christian DR, Huber A, Brecht ML, McCann MJ, Marinelli-Casey P, Lord RH, Reiber C, Lu TH; Methamphetamine Treatment Project, Galloway GP.

Subst Use Misuse. 2007;42(14):2207-22.

PMID:
18098001
38.

Asymmetric dimethylarginine (ADMA)--a modulator of nociception in opiate tolerance and addiction?

Kielstein A, Tsikas D, Galloway GP, Mendelson JE.

Nitric Oxide. 2007 Sep;17(2):55-9. Epub 2007 Jun 7. Review.

39.

Factor analysis of the Alcohol and Drug Confrontation Scale (ADCS).

Polcin DL, Galloway GP, Bostrom A, Greenfield TK.

Addict Behav. 2007 Oct;32(10):2274-80. Epub 2007 Jan 11.

40.

Attentional control and brain metabolite levels in methamphetamine abusers.

Salo R, Nordahl TE, Natsuaki Y, Leamon MH, Galloway GP, Waters C, Moore CD, Buonocore MH.

Biol Psychiatry. 2007 Jun 1;61(11):1272-80. Epub 2006 Nov 9.

PMID:
17097074
41.

A treatment model for craving identification and management.

Stalcup SA, Christian D, Stalcup J, Brown M, Galloway GP.

J Psychoactive Drugs. 2006 Jun;38(2):189-202. Review.

PMID:
16903458
42.

Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers.

Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J, Galloway GP, Koeppe RA, Kilbourn MR, Robbins T, Schuster CR.

Psychopharmacology (Berl). 2006 Apr;185(3):327-38. Epub 2006 Mar 3. Erratum in: Psychopharmacology (Berl). 2006 Jul;186(4):620.

43.

Measuring confrontation during recovery from addiction.

Polcin DL, Galloway GP, Greenfield TK.

Subst Use Misuse. 2006;41(3):369-92.

PMID:
16467012
44.

Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study.

Nordahl TE, Salo R, Natsuaki Y, Galloway GP, Waters C, Moore CD, Kile S, Buonocore MH.

Arch Gen Psychiatry. 2005 Apr;62(4):444-52.

PMID:
15809412
45.
46.

A dissociation in attentional control: evidence from methamphetamine dependence.

Salo R, Nordahl TE, Moore C, Waters C, Natsuaki Y, Galloway GP, Kile S, Sullivan EV.

Biol Psychiatry. 2005 Feb 1;57(3):310-3.

PMID:
15691533
47.

Psychiatric symptoms in methamphetamine users.

Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, Iguchi M; Methamphetamine Treatment Project.

Am J Addict. 2004 Mar-Apr;13(2):181-90.

PMID:
15204668
48.

A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence.

Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A, Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber A, McCann MJ, Obert J, Pennell S, Reiber C, Vandersloot D, Zweben J; Methamphetamine Treatment Project Corporate Authors.

Addiction. 2004 Jun;99(6):708-17.

PMID:
15139869
49.

The case for high-dose motivational enhancement therapy.

Polcin DL, Galloway GP, Palmer J, Mains W.

Subst Use Misuse. 2004 Jan;39(2):331-43. Review.

PMID:
15061564
50.

Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. Magnetic resonance spectroscopy.

Nordahl TE, Salo R, Possin K, Gibson DR, Flynn N, Leamon M, Galloway GP, Pfefferbaum A, Spielman DM, Adalsteinsson E, Sullivan EV.

Psychiatry Res. 2002 Nov 30;116(1-2):43-52.

PMID:
12426033

Supplemental Content

Loading ...
Support Center